CCNO and glioblastoma: Specifically, TTFields-induced downregulation of the FA-BRCA pathway promotes a synergistic interaction between TTFields and CCNU in MGMT promoter methylated GBM cells, and underscore the previously described clinical benefit of adding TTFields therapy to the CeTeG regimen for patients with a methylated MGMT promoter.